Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Bio-Rad to Acquire MorphoSys's Research and Diagnostic Antibody Business AbD Serotec

MARTINSRIED / MüNCHEN, GERMANY -- (Marketwire) -- 12/16/12 --

MorphoSys AG / Bio-Rad to Acquire MorphoSys's Research and Diagnostic Antibody Business AbD Serotec . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys to Increase Focus on Therapeutics

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has agreed to sell its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, Inc. (NYSE: BIO), a multinational manufacturer and distributor of life science research and clinical diagnostic products. The total consideration amounts to approximately EUR 53 million and will be settled in cash. The total consideration comprises the purchase price, compensation for cash reserves in the AbD Serotec companies in the amount of approximately EUR 5 million and a license payment for the use of the HuCAL technology in the research and diagnostic markets. The transaction is subject to certain closing conditions, and is expected to be completed in January, 2013.

"This transaction was done to enable an increased focus on our therapeutic business segment", commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "We are making great progress in our therapeutic antibody pipeline, which is a huge potential value driver for MorphoSys. With the sale of AbD Serotec, we will bring a laser-like focus to driving growth in this, our area of core competence."

According to the terms of the transaction, Bio-Rad Laboratories will acquire all of MorphoSys's AbD Serotec research reagent and diagnostic business, comprising the AbD Serotec segment of MorphoSys AG as well as the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc. In addition, the transaction includes a fully paid-up, non-exclusive license agreement to use MorphoSys's HuCAL technology for diagnostic and research purposes.

"As a result of today's transaction MorphoSys will concentrate on technology and drug development. It enables us to fully dedicate our financial resources to the most significant value drivers," commented Jens Holstein, Chief Financial Officer of MorphoSys AG. "Bio-Rad provides AbD Serotec and its employees with an ideal environment in which to exploit its potential in the research and diagnostic arena."

MorphoSys will hold a public conference call and webcast tomorrow, Monday, December 17, 2012 at 02:00 p.m. CET (08:00 a.m. EST, 01:00 p.m. BST) to present more information on the AbD Serotec / Bio-Rad transaction.

Dial-in number for the Conference Call (listen-only): Germany: +49 89 2444 32975 For U.K. residents: +44 20 3003 2666 For U.S. residents: +1 202 204 1514

Please dial in 10 minutes before the beginning of the conference.

In addition, MorphoSys offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at http://www.morphosys.com/conference-calls.

A live webcast, slides, webcast replay and transcript will be made available at http://www.morphosys.com/conference-calls.

About MorphoSys: MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®) and Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of MorphoSys AG.

Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

Media Release (PDF): http://hugin.info/130295/R/1665464/540350.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE [HUG#1665464]

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
Most forward-looking CEOs have already made their move to prepare for the future that they foresee – where business technology is a key deciding factor for them to attain ongoing commercial prosperity. This new digital-propelled environment will profoundly change business processes, al...
For the third year in a row, we worked together with Pacific Crest Securities, an investment banking firm with a specific focus on SaaS, to survey 306 SaaS companies. This represents nearly double the # of respondents from last year, giving us deeper benchmarking data and insights to s...
If you're an executive that's concerned about the high-cost of proprietary software, you're not alone. If your IT team pushes back whenever Line of Business leaders ask them for feature enhancements that goes beyond the limits of the commercial software packages they've licensed, then ...

The Internet of Things: Another Silicon Valley invention to get all excited about? Or is it something that will hold up beyond the California border and next January? If you’re aching to know, then I suggest you attend the upcoming “Monetizing the ‘Internet of Things’” presentation ...

Transformed traditional IT must act as the enterprise “traffic cop” – a good cop that keeps agile teams from crossing the compliance/security line, making sure that interactions among such teams play by a consistent, consistently evolving set of rules. Coordinate and facilitate sharin...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE